EP300 and prostate cancer: IRF-1 can recruit p300/CBP to increase transcription of PD-L1 and abrogating this process by a p300/CBP inhibitor intensely increased the efficacy of PD-L1 blockade treatment in prostate cancer (72) (Figure 3).